Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

Boehringer moves interferon-free hep C regimen into phase III

Oral combination drug achieved viral cure rate of up to 85 per cent in phase IIb

- PMLiVE

Good practice in cancer care recognised at UK awards

Sir Mike Richards honoured with lifetime achievement award at QiC Excellence in Oncology 2012

- PMLiVE

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

Joined by John Womelsdorf who is appointed VP business development

- PMLiVE

Malaria charity calls up Ladbury PR to handle comms

Comes as Malaria No More UK partners with ITV’s I’m A Celebrity…Get Me Out Of Here

- PMLiVE

Idea Pharma adds to its medical investigation team

Appoints Partha Ghosh from Parexel and Peter Wootton from AstraZeneca

- PMLiVE

Moving with the times: pharma market research and digital

As digital technology continues to transform the world around us, pharmaceutical market researchers are harnessing its potential to capture vital insights from healthcare stakeholders

- PMLiVE

NHS needs to invest for longer term savings, says ABPI

Chief executive Stephen Whitehead accuses health service of not seizing innovation

- PMLiVE

Watson selects global generics management team

Will be led by Sigurdur Oli Olafsson, a former Actavis CEO

- PMLiVE

GSK and XenoPort end restless legs syndrome collaboration

Follows tough approval period for Horizant and subsequent poor sales 

- PMLiVE

NICE to reverse approval for Novartis’ asthma drug Xolair

Draft guidance doesn't recommend omalizumab for severe asthma

- PMLiVE

Novo Nordisk’s new insulin moves closer to US approval

Follows recommendation in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links